Loading
The European gynaecological oncology, radiotherapy and pathology societies' joint guideline integrates molecular classification into risk groups for endometrial cancer and sets adjuvant treatment for each, including no adjuvant therapy for early POLE-mutated tumours.
Joint evidence-based guideline covering diagnosis, molecular classification, surgical staging including sentinel node mapping, risk group definitions incorporating molecular class, adjuvant radiotherapy and chemotherapy recommendations, fertility-sparing treatment, and management of advanced and recurrent disease.
The adjuvant recommendations on this site's endometrial subtype pages (observation for stage I to II POLE-mutated disease, chemotherapy for p53-abnormal tumours with myometrial invasion, brachytherapy for intermediate risk) follow this guideline.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/